Breaking Research News from sources other than Breastcancer.org
Comments
-
For those who are HER2+ -- this just appeared in the National Cancer Institute newsletter about two new treatments
https://www.cancer.gov/news-events/cancer-currents...
0 -
https://www.practiceupdate.com/C/94747/56?elsca1=emc_enews_topic-alert
Re: Clinical and pathological factors influencing risk of late distant recurrence in ER+ ILC
0 -
Murfy - thank you for the lymphedema post. I will ask the DR. Right now my DR is very hopeful that the Ibrance will knock out the tumor in the axilla causing it, and that no more treatment will be needed. It is on the contraleteral side where lymphnodes removed. Have you heard anything about the success rate of surgery for lymphedema? DR, a surgeon, and lymphatic therapist not confident in surgery approach, not available in my state.
2009 - Left. Lumpectomy, 2 nodes checked, radiation, tamoxifen 5 years
2016 Left, again. Chemo, bi-lateral (my choice), AI initially, switched to tamoxifen (SEs)
2019 - Sweeling in right arm. Scans and biopsy revealed cancer in R- A axilla. Now on Ibrance.
0 -
Molecule 'selectively killed [triple negative] cancer cells,'
[A] small molecule discovered in animals on the seabed off the coast of Bjørnøya in 2011 [is being investigated for its effects on caner].
The molecule is part of a so-called hydroid – a collection of single cells joined together in a plant-like form and stuck on the seabed. Tests of its impact on multiple cell lines revealed many that were unaffected, but breast cancer cells showed the greatest impact.
The largest impact was the samples against a special type of breast cancer cells including triple-negative breast cancer...
"If it can be developed into a medicine, it will be a completely new treatment alternative for a group of cancer patients who now have limited treatment options," [Kine Østnes Hansen, an associate researcher at UiT Norway's Arctic University] said.
0 -
Flu vaccines may shrink tumors and boost cancer treatment
0 -
nice one Marijen
0 -
0
-
That is pretty amazing Bev/Jen. It's good for 10 autoimmune diseases and fatty liver. I wonder what the autoimmune diseases are as a lot of us have them.
0 -
Wow! Thanks for posting!
0 -
Marijen,
I also wonder if this would be applicable to non-TNBC cancer at some point, since it sure sounds like some kind of wonder drug.
0 -
another nice one BevJen!
0 -
Thanks BevJen, I think Leronlimab is also for other types, as CCR5 expression could be observed in many different cancers....
0 -
How proton radiotherapy can kill cancer in milliseconds
New research in mice shows "for the first time" that scientists can use protons to administer radiation therapy in a matter of milliseconds, killing cancer cells while protecting healthy tissue.
https://www.medicalnewstoday.com/articles/327476.p...0 -
New Cardiac Abnormalities Following Radiation Therapy in Breast Cancer Patients Treated With Trastuzumab
- "This retrospective study was designed to evaluate imaging abnormalities following modern radiation therapy and trastuzumab for breast cancer. Left-sided radiation was associated with an increase in new cardiac abnormalities. The incidence of new abnormalities correlated with radiation dose exposure." – Neil Majithia, MD
- New cardiac abnormalities appear to be relatively common among patients with breast cancer treated with trastuzumab plus radiation. Further studies are warranted to evaluate the long-term clinical significance of these abnormalities seen on imaging.
0 -
Molecular Imaging to Identify Patients With Metastatic Breast Cancer Who Benefit From Endocrine Treatment Combined With Cyclin-Dependent Kinase Inhibition
- This study was designed to evaluate the predictive benefit of positron-emission tomography with estrogen-tagged labeling (FES-PET) for 27 patients with ER+ breast cancer treated with letrozole and palbociclib. The median time to progression was 73 weeks in those with 100% FES-positive disease versus 27 weeks in heterogenous FES-positive disease and 15 weeks in those without FES positivity.
- FES-PET may identify patients with ER+ breast cancer who will benefit from the addition of a cyclin-dependent kinase inhibitor to letrozole.
Commentary by Lillie D Shockney RN, BS, MAS, ONN-CGIt is wonderful to see that FES-PET may provide a means of helping to determine which patients with hormone receptor–positive metastatic disease may benefit most from endocrine treatment combined with a CDK-inhibiting drug. The authors discuss the difficulties in obtaining biopsies from metastatic lesions, which can be correct in some cases. A bigger issue, however, is that, in many cases, no attempt is made at all, and treatment remains based on the primary lesion in the breast to determine the prognostic factors of the metastatic lesions, which is a mistake and a violation in the standard of care.
Whatever can be done to make it easier on the patient (biopsies of other organ sites are quite painful) and potentially more accurate in determining the degree of positivity of each metastatic organ site can really go a long way in potentially helping to determine who are the right candidates for this therapy. Those benefiting seem to benefit for a long time, which is wonderful, truly making this disease a chronic illness that is manageable.
0 -
Things are changing! "Innovators have invented a better way for surgeons to locate tumors during lumpectomies for breast cancer."
0 -
umakemehappy ...GPS guided surgery. That's really exciting. For surgeons for sure. Interesting reading. Thanks!
0 -
Inclusion of endogenous plasma dehydroepiandrosterone sulphate and mammographic density in risk prediction models for breast cancer
Marike Gabrielson, Kumari A. Ubhayaseker, Santosh R. Acharya, Mikael Andersson Franko, Mikael Eriksson, Jonas Bergquist, Kamila Czene and Per Hall
DOI: 10.1158/1055-9965.EPI-19-11Abstract
Background Endogenous hormones and mammographic density are risk factors for breast cancer. Joint analyses of the two may improve the ability to identify high-risk women. Methods This study within the KARMA cohort included pre-diagnostic measures of plasma hormone levels of dehydroepiandrosterone (DHEA), its sulphate (DHEAS) and mammographic density in 629 cases and 1,223 controls, not using menopausal hormones. We evaluated the area under the receiver-operating curve (AUC) for risk of breast cancer by adding DHEA, DHEAS, and mammographic density, to the Gail or Tyrer-Cuzick 5-year risk scores or the CAD2Y 2-year risk score. Results DHEAS and percentage density were independently and positively associated with breast cancer risk (P=0.007 and P<0.001, respectively) for postmenopausal, but not premenopausal, women. No significant association was seen for DHEA. In postmenopausal women, those in the highest tertiles of both DHEAS and density were at greatest risk of breast cancer (odds ratio (OR) 3.5; 95% confidence interval (CI) 1.9-6.3) compared to the lowest tertiles. Adding DHEAS significantly improved the AUC for the Gail (+2.1 units, P=0.008) and Tyrer-Cuzick (+1.3 units, P=0.007) risk models. Adding DHEAS to the Gail and Tyrer-Cuzick models already including mammographic density further increased the AUC by 1.2 units, (P=0.006) and 0.4 units (P=0.007), respectively, compared to only including density. Conclusion DHEAS and mammographic density are independent risk factors for breast cancer and improve risk discrimination for postmenopausal breast cancer. Impact Combining DHEAS and mammographic density could help identify women at high risk who may benefit from individualised breast cancer screening and/or preventive measures among postmenopausal women.
- Received September 11, 2019.
- Revision received November 6, 2019.
- Accepted January 10, 2020.
- Copyright ©2020, American Association for Cancer Research.
0 -
Acid reflux drugs may have negative side effects for breast cancer survivors
New Ohio State University research shows an association between breast cancer survivors' use of proton pump inhibitors (PPIs) and reports of problems with concentration and memory. On average, cognitive problems reported by PPI users were between 20 and 29 percent more severe than issues reported by non-PPI users. PPIs are sold under such brand names as Nexium, Prevacid and Prilosec.
https://www.sciencedaily.com/releases/2020/01/200117110840.htm
Study DOI: 10.1007/s11764-019-00815-4
0 -
Some happy reading!
Immune cell which kills most cancers discovered by accident by British scientists in major breakthrough
.
0 -
Interesting article Kanga Roo. From the article it sounds like they plan to start doing human trials maybe in November. I wonder if this is doing well in trials how long we would have to wait before it could be made available...5 to 10 years? I don't know what the timeframes are in the UK for new treatments. Does the UK have the "Right to Try" like the USA now has?
0 -
I hope we here more about this 'new' immune cell! wow! Exciting!
0 -
Oh my gosh, billions spent on cancer research and they find this by accident! I hope it lives up to even a fraction of its potential!
0 -
Dear all, what Kanga_Roo posted... That would be so crazy... I don't know even what to say, and although sounds "too easy and good to be true", CAR-T was just the same genius story, which we have already forgotten - we simply use these therapies today. Let's hope for the best, let's hold on!
Husband Saulius
0 -
Not as dramatic, but more upbeat reading...
Dozens of non-oncology drugs [have newly discovered ability to] kill cancer cells
Researchers tested approximately 4,518 drug compounds on 578 human cancer cell lines and found nearly 50 that have previously unrecognized anti-cancer activity. These drugs have been used to treat conditions such as diabetes, inflammation, alcoholism, and even arthritis in dogs.,,
The surprising findings, which also revealed novel drug mechanisms and targets, suggest a possible way to accelerate the development of new cancer drugs or repurpose existing drugs to treat cancer.
https://www.sciencedaily.com/releases/2020/01/200120113130.htm0 -
UW-Madison professors create revolutionary GPS device to help surgeons find breast cancer tumors during removal
Before the SmartClip, for the last 70 years, when doctors biopsy a breast cancer tumor, they also insert a little clip at the center of the tumor. But when it comes time to remove the tumor, surgeons can't see where that clip is...
In order for the surgeons to know where the tumor is, right before surgery a radiologist has to mark the area with a wire [which is stressful for patients].
The SmartClip is streamlining the breast cancer removal process. It can be placed during biopsy weeks or months before surgery, cutting out an additional procedure and possible scheduling conflicts with the radiology department.
0 -
Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium
Cancer Epidemiol Biomarkers Prev; Published OnlineFirst December 2, 2019; doi:10.1158/1055-9965.EPI-19-0546
http://cebp.aacrjournals.org/content/early/2020/01/21/1055-9965.EPI-19-0546.abstract
0 -
A Trickster Enters the Fight Against Metastatic Cancers - Scientific American
https://www.scientificamerican.com/custom-media/a-trickster-enters-the-fight-against-metastatic-cancers/?mvt=i&mvn=5f65a57f546f4dcca5ab47f6dfda6a55&mvp=NA-SCIEAMERLIVE-11237933&mvl=HomePopular
0 -
Lumpie, are you ok and just taking a break? Just wondering if things a reasonably OK with you
0 -
Karenfizedbo15: you are so thoguhtful to be concerned! Doing pretty well here actually. Recent scans were stable - yeah! I've just slowed down a bit. Had *a lot* going on on the personal side. Needed some down time over the holidays. Kinda got overwhelmed with the amount of (good) info (some of it repetitive) coming out of San Antonio. And after that... seems like there is a lot of stuff that is either of marginal value or such early bench science that ... i have to try not to get disillusioned about how long it will take to turn into anything actionable. Did I mention that my washer died? How's that for all over the board? Thanks for checking in!
0
